Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5604076 | 0.82 | EGLN1 (0.31) | EGLN1 | |
| SCHEMBL17387416 | 0.78 | MMP1 (0.33) | — | |
| SCHEMBL3795506 | 0.77 | MVD (0.33) | — | |
| SCHEMBL10428978 | 0.74 | KMT2A (0.57) | POLBTSHREPHX1EPHX2 | |
| SCHEMBL1810893 | 0.72 | MMP1 (0.32) | — | |
| SCHEMBL2486025 | 0.70 | PRMT1 (0.42) | EGLN1EPHX1EPHX2 | |
| SCHEMBL1867565 | 0.69 | EPHX1 (0.50) | SMN1; SMN2EPHX1EPHX2KDM4E | |
| SCHEMBL1038146 | 0.69 | MMP1 (0.32) | EPHX1 | |
| SCHEMBL960688 | 0.69 | MMP1 (0.32) | TSHRSMN1; SMN2KDM4E | |
| SCHEMBL305474 | 0.68 | CAD (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379118-B1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GEN ELECTRIC (US) | 2017-10-18 | — | — | EP | claimed |
| US-20140147387-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GENERAL ELECTRIC COMPANY (US) | 2014-05-29 | — | — | US | claimed |
| US-8728529-B2 | Nanoparticle contrast agents for diagnostic imaging | GENERAL ELECTRIC COMPANY (US) | 2014-05-20 | — | — | US | claimed |
| US-20100166665-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GENERAL ELECTRIC COMPANY (US) | 2010-07-01 | — | — | US | claimed |
| US-20100166664-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GENERAL ELECTRIC COMPANY (US) | 2010-07-01 | — | — | US | claimed |
| EP-2379118-B1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GEN ELECTRIC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-9585974-B2 | Nanoparticle contrast agents for diagnostic imaging | GENERAL ELECTRIC COMPANY (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160296641-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GE HEALTHCARE LIMITED (GB) | 2016-10-13 | — | — | US | disclosed |
| US-9399075-B2 | Nanoparticle contrast agents for diagnostic imaging | GENERAL ELECTRIC COMPANY (US) | 2016-07-26 | — | — | US | disclosed |
| US-20140147387-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GENERAL ELECTRIC COMPANY (US) | 2014-05-29 | — | — | US | disclosed |
| US-8728529-B2 | Nanoparticle contrast agents for diagnostic imaging | GENERAL ELECTRIC COMPANY (US) | 2014-05-20 | — | — | US | disclosed |
| EP-2379118-A2 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | General Electric Company (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010076237-A2 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GENERAL ELECTRIC COMPANY (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100166665-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GENERAL ELECTRIC COMPANY (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100166664-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | GENERAL ELECTRIC COMPANY (US) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160296641-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | CD47, CD63, MACO1 | POLB 3782/4885TSHR 1547/4885EGLN1 2400/4885 |
| US-20140147387-A1 | NANOPARTICLE CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | CD47, CD63, MACO1 | POLB 3782/4885TSHR 1547/4885EGLN1 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.